DK1434603T3 - Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater - Google Patents

Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater

Info

Publication number
DK1434603T3
DK1434603T3 DK02789173.8T DK02789173T DK1434603T3 DK 1434603 T3 DK1434603 T3 DK 1434603T3 DK 02789173 T DK02789173 T DK 02789173T DK 1434603 T3 DK1434603 T3 DK 1434603T3
Authority
DK
Denmark
Prior art keywords
ligand
pathogenic cells
immunogen
population
immune response
Prior art date
Application number
DK02789173.8T
Other languages
English (en)
Inventor
Philip Stewart Low
Yingjuan Lu
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of DK1434603T3 publication Critical patent/DK1434603T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK02789173.8T 2001-09-28 2002-09-26 Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater DK1434603T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32579301P 2001-09-28 2001-09-28
US32633201P 2001-10-01 2001-10-01
US39165402P 2002-06-26 2002-06-26
PCT/US2002/030546 WO2003028634A2 (en) 2001-09-28 2002-09-26 Method of treatment using ligand-immunogen conjugates

Publications (1)

Publication Number Publication Date
DK1434603T3 true DK1434603T3 (da) 2010-04-26

Family

ID=32738720

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02789173.8T DK1434603T3 (da) 2001-09-28 2002-09-26 Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater

Country Status (10)

Country Link
US (1) US20030086900A1 (da)
EP (2) EP2168598A1 (da)
JP (1) JP2005523878A (da)
KR (1) KR20040053136A (da)
AT (1) ATE451935T1 (da)
CA (1) CA2461877A1 (da)
DE (1) DE60234782D1 (da)
DK (1) DK1434603T3 (da)
ES (1) ES2338305T3 (da)
WO (1) WO2003028634A2 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
PL211872B1 (pl) * 2000-03-31 2012-07-31 Purdue Research Foundation Kompozycja farmaceutyczna
WO2002085908A1 (en) * 2001-04-24 2002-10-31 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
JP4868698B2 (ja) * 2001-05-02 2012-02-01 パーデュー・リサーチ・ファウンデーション マクロファージが仲介する疾患の治療および診断
EP1414946A2 (en) * 2001-07-31 2004-05-06 Francesca Granucci Dendritic cells and the uses thereof in screening cellular targets and potential drugs
AR039429A1 (es) * 2002-04-19 2005-02-16 Endocyte Inc Metodo para aumentar la eliminacion especifica mediada por la respuesta inmune endogena de la poblacion de celulas patogenicas en un animal huesped inmunizado previamente, composicion y combinacion que comprenden un auxiliar th1 y un conjugado hapten-portador de utilidad en el mismo.
US7910594B2 (en) * 2002-05-15 2011-03-22 Endocyte, Inc. Vitamin-mitomycin conjugates
NZ541846A (en) 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
RU2341289C2 (ru) * 2003-02-21 2008-12-20 ХАСУМИ Эл-Эл-Си (Ди-Би-Эй ШУКОКАЙ ИНТЕРНЭШНЛ) Способ усиления иммунного ответа на антиген у млекопитающих
JP2007526238A (ja) * 2003-05-06 2007-09-13 パーデュー・リサーチ・ファウンデーション マクロファージまたは葉酸受容体を標的とする狼瘡治療法
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
EP1701736A4 (en) * 2003-12-24 2008-05-07 Inst Medical W & E Hall THERAPEUTIC AGENTS AND USES
WO2005097993A2 (en) * 2004-02-19 2005-10-20 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
WO2006080946A2 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US8044200B2 (en) * 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
EP1864133B1 (en) * 2005-03-30 2010-03-10 Purdue Research Foundation Method for breastcancer prognosis using cellular folate vitamin receptor quantification
US20070009434A1 (en) * 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
WO2007022494A2 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
EP1951740B1 (en) 2005-11-10 2014-07-16 James Paulson High affinity siglec ligands
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
WO2007095316A2 (en) * 2006-02-15 2007-08-23 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
AU2008213702B2 (en) 2007-02-07 2014-04-24 Purdue Research Foundation Positron emission tomography imaging method
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) * 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
WO2008148001A2 (en) * 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
JP2011500835A (ja) 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
WO2013130776A1 (en) 2012-02-29 2013-09-06 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
KR20150070318A (ko) 2012-10-16 2015-06-24 엔도사이트, 인코포레이티드 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법
CN104797247A (zh) 2012-11-15 2015-07-22 恩多塞特公司 用于治疗由psma表达细胞引起的疾病的共轭物
PE20211760A1 (es) 2013-10-18 2021-09-07 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma) que comprenden grupos carboxilicos y una region de enlazador modificada, agentes formadores de imagenes y agentes farmaceuticos que los comprenden
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
US12397059B2 (en) 2019-07-08 2025-08-26 Purdue Research Foundation Compounds and methods for the treatment and prevention of fibrotic disease states and cancer

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816110A (en) * 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US4314988A (en) * 1979-10-31 1982-02-09 Baker Instruments Corp. Folic acid derivatives and process for preparation
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US4659655A (en) * 1981-11-25 1987-04-21 Bio-Response, Inc. Method for isolating product-producing cells
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
JP2534222B2 (ja) * 1982-05-12 1996-09-11 プレジデント アンド フエロウズ オブ ハ−バ−ド カレツジ 混成タンパク質生産用融合遺伝子
NL8401226A (nl) * 1984-04-16 1985-11-18 Univ Utrecht Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5117022A (en) * 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
JPS6479125A (en) * 1986-08-13 1989-03-24 Takeda Chemical Industries Ltd Antitumor agent
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
DE69023900T4 (de) * 1989-02-24 1996-10-02 The Regents Of The University Of California, Berkeley, Calif. Gentechnologisch veränderte immunglobuline.
US5075287A (en) * 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5217881A (en) * 1989-04-25 1993-06-08 Immunex Corporation Hyperglycosylated cytokine conjugates
JPH0686375B2 (ja) * 1989-09-25 1994-11-02 大塚製薬株式会社 リポソーム製剤
WO1992003569A1 (en) * 1990-08-29 1992-03-05 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
ES2096215T3 (es) * 1992-10-01 1997-03-01 Wellcome Found Tucaresol como agente inmunopotenciador.
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
WO1994021275A1 (fr) * 1993-03-19 1994-09-29 Vacsyn S.A. Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US5602171A (en) * 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
CA2218737C (en) * 1996-04-10 2003-12-16 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
WO1997042347A2 (en) * 1996-05-06 1997-11-13 Brigham And Women's Hospital 5-lipoxygenase gene polymorphisms and their use in classifying patients
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AU732856B2 (en) * 1997-05-20 2001-05-03 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
AU1095799A (en) * 1997-10-17 1999-05-10 Philip L. Fuchs Folic acid derivatives
KR100399475B1 (ko) * 1998-02-12 2003-09-29 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 순환 중인 암세포의 신속하고 효과적인 분리 방법 및 이를위한 제제
WO2000009075A2 (en) * 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
US6960449B2 (en) * 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
AUPQ071299A0 (en) * 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
PT1242060E (pt) * 1999-08-17 2006-08-31 Glaxo Group Ltd Tratamento da doenca metastatica
JP4948728B2 (ja) * 1999-08-17 2012-06-06 パーデュー・リサーチ・ファウンデーション 癌診断用抗体
DK1221955T3 (da) * 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
JP2003510290A (ja) * 1999-09-27 2003-03-18 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激核酸誘導インターフェロンに関する方法
US20020039583A1 (en) * 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
JP2003527352A (ja) * 2000-01-13 2003-09-16 アンティジェニクス インコーポレーテッド Ｃｐｇおよびサポニンの自然免疫刺激化合物、ならびにそれらの方法
PL211872B1 (pl) * 2000-03-31 2012-07-31 Purdue Research Foundation Kompozycja farmaceutyczna
AR039429A1 (es) * 2002-04-19 2005-02-16 Endocyte Inc Metodo para aumentar la eliminacion especifica mediada por la respuesta inmune endogena de la poblacion de celulas patogenicas en un animal huesped inmunizado previamente, composicion y combinacion que comprenden un auxiliar th1 y un conjugado hapten-portador de utilidad en el mismo.
NZ541846A (en) * 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells

Also Published As

Publication number Publication date
CA2461877A1 (en) 2003-04-10
WO2003028634A2 (en) 2003-04-10
DE60234782D1 (de) 2010-01-28
EP1434603A4 (en) 2005-11-30
KR20040053136A (ko) 2004-06-23
ATE451935T1 (de) 2010-01-15
JP2005523878A (ja) 2005-08-11
EP1434603B1 (en) 2009-12-16
US20030086900A1 (en) 2003-05-08
WO2003028634A3 (en) 2003-10-16
EP2168598A1 (en) 2010-03-31
WO2003028634A8 (en) 2004-07-29
EP1434603A2 (en) 2004-07-07
ES2338305T3 (es) 2010-05-06

Similar Documents

Publication Publication Date Title
DK1434603T3 (da) Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater
BR0109704A (pt) Método de tratamento usando conjugados de imunógeno ligando
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
DK1594542T3 (da) Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
CY1111814T1 (el) Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων
LU92133I9 (da)
EE200200578A (et) Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid
FR12C0001I2 (fr) Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
CY1108384T1 (el) Διαδερμικη δοσολογια βουπρενορφινης για αναλγησια
EA200100610A1 (ru) Конъюгат гаптен-носитель (варианты), антитело и способ его получения, функциональный фрагмент антитела, набор для определения присутствия никотина в образце, вакцинная композиция (варианты) и способ профилактики или лечения никотиновой аддикции (варианты)
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
TR200202231T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
DE69925830D1 (de) Peg-lhrh analog konjugate
DE60045847D1 (de) Rezeptorbindende konjugate
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DK1276501T3 (da) Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi
DE60139954D1 (de) Immunmodulatorische konstruktionen und ihre verwendung
BRPI0518619A2 (pt) mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica
DK1399186T3 (da) Lægemiddel til behandling af tumorer og disses metastaser under anvendelse af et bindemolekyle mod knogle-sialoprotein
DK1377320T3 (da) Polynukleotidbindingskomplekser omfattende steroler og saponiner